Halozyme Therapeutics (HALO) Operating Income (2010 - 2026)
Halozyme Therapeutics (HALO) reported Operating Income of $184.5 million for Q1 2026, up 30.37% year-over-year from $141.5 million in Q1 2025, and up 298.64% quarter-over-quarter from -$92.9 million in Q4 2025.
Halozyme Therapeutics (HALO) Operating Income (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 17 years of Operating Income data on file, last reported at $184.5 million in Q1 2026.
- Operating Income for Q1 2026 came in at $184.5 million, up 30.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $512.0 million (down 14.31% YoY), and the FY2025 annual result was $469.0 million, down 14.95% from the prior year.
- Operating Income grew to $184.5 million in Q1 2026 per HALO's latest filing, from -$92.9 million in the prior quarter.
- Over five years, Operating Income peaked at $217.9 million in Q3 2025 and troughed at -$92.9 million in Q4 2025.
- A 5-year average of $106.5 million and a median of $95.5 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2025: Operating Income surged 177.33% in 2023, then tumbled 152.93% in 2025.
- A 5-year view of Operating Income shows it stood at $74.5 million in 2022, then jumped by 35.6% to $101.0 million in 2023, then jumped by 73.7% to $175.5 million in 2024, then plunged by 152.93% to -$92.9 million in 2025, then jumped by 298.64% to $184.5 million in 2026.
- Business Quant data shows HALO's Operating Income at $184.5 million in Q1 2026, -$92.9 million in Q4 2025, and $217.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -65.83 Mn |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | 184.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 184.52 Mn |
| Dec 31, 2025 | -92.89 Mn |
| Sep 30, 2025 | 217.92 Mn |
| Jun 30, 2025 | 202.44 Mn |
| Mar 31, 2025 | 141.54 Mn |
| Dec 31, 2024 | 175.50 Mn |
| Sep 30, 2024 | 163.20 Mn |
| Jun 30, 2024 | 117.24 Mn |
| Mar 31, 2024 | 95.54 Mn |
| Dec 31, 2023 | 101.04 Mn |
| Sep 30, 2023 | 88.28 Mn |
| Jun 30, 2023 | 94.46 Mn |
| Mar 31, 2023 | 53.80 Mn |
| Dec 31, 2022 | 74.51 Mn |
| Sep 30, 2022 | 83.29 Mn |
| Jun 30, 2022 | 34.06 Mn |
| Mar 31, 2022 | 75.67 Mn |
| Dec 31, 2021 | 56.53 Mn |
| Sep 30, 2021 | 75.59 Mn |
| Jun 30, 2021 | 93.05 Mn |